2019

• business2019/09/20

  AskAt Inc. Executes Licensing and Business Agreement for CB2 Receptor Agonist AAT-730 with Oxford Cannabinoid Technologies

  AskAt Inc. (Headquarters, Nagoya, Japan; President, Akihiro Furuta) today announced an agreement with Oxford Cannabinoid Technologies (Headquarters, London, UK; Chairman, Neil Mahapatra) which includes the option to license AAT-730, AskAt’s CB2 receptor agonist.
  AskAt Inc. will receive a research collaboration payment, and, in the event the license is exercised by Oxford Cannabinoid Technologies, a licensing fee, development milestone payments, and sales royalty payments. Specific milestone and payment terms have not been disclosed by the companies.
  CB2 Receptor Agonist AAT-730
  Cannabinoid receptors are a traditional drug target for pain and neurological disease therapy. Recent scientific research on cannabinoids has revealed the potential of the CB2 receptor, one of two cannabinoid receptors, as a molecular target for neuropathic pain, cancer pain, neurodegenerative disease, such as Alzheimer’s and Parkinson’s diseases, neuroinflammatory diseases, cancer, and diabetes. CB1 and CB2 each have different distribution profiles and pharmacological functions in the human body. A number of pharmaceutical companies have attempted to develop CB2-selective agonists without CB1-mediated neurological side effects, however without success. AskAt is developing AAT-730, a small molecule and highly selective CB2 agonist, with no CB1-related untoward effects, and potent CB2-mediated pharmacological efficacy in in vivo studies
  Oxford Cannabinoid Technologies
  Oxford Cannabinoid Technologies is a biopharmaceutical company established to combine cannabinoid medicine with world-class scientific research. The company’s current research areas for cannabinoid-based therapies include pain, oncology, inflammatory diseases and neurological disorders. Please refer the company’s web page for details.

• patent2019/09/20

  Mexican Institute of Industrial Property Granted AskAt a Use Patent of EP4 Receptor Antagonist for the Treatment of Cancer

  AskAt received a notice of allowance dated August 13, 2019 from the Mexican Institute of Industrial Property (IMPI: Instituto Mexicano de la Propiedad Industrial) in connection with the Mexican Patent Application No. MX/a/2016/008394, a use patent of EP4 receptor antagonist for the treatment of cancer.

• business2019/08/15

  Galliprant® Approved in Brazil

  On August 13, 2019, Elanco Animal Health Inc., (Indiana USA, Elanco), announced
  that GALLIPRANT®
  , an EP4 receptor antagonist, was approved in Brazil for the
  treatment of pain associated with osteoarthritis in dogs.
  For details, please refer the announce by Elanco.
  https://www.elanco.com/news/press-releases/elanco-q2-earnings

• patent2019/07/16

  United States Patent and Trademark Office Granted AskAt a Cartilage Disease Use Patent of EP4 Antagonist

  AskAt received a notice of allowance and a notice of allowability dated June 26, 2019 from the United States Patent and Trademark Office (USPTO) in connection with the U.S. Patent Application No. 15/911,567, a cartilage disease use patent of EP4 antagonist.

• patent2019/07/10

  Galliprant® Granted Supplementary Protection Certificate (SPC) in France

  Germany granted SPC for Galliprant® on June 26, 2019, a veterinary drug product developed by
  Aratana Therapeutics Inc. (Aratana), and marketed by Aratana and Elanco Animal Health Inc.
  (Elanco). The SPC extends the period of exclusive sales rights for Galliprant® until February 28,
  2031. Additional SPCs for Galliprant® are currently under examination in several major EU
  countries. The grant in France marks the fifth approval in the EU, following grants received in Italy,
  Holland, Spain and Germany.
  
  
  Galliprant®
  Galliprant® (grapiprant tablets) is a prostaglandin E2 (PGE2) EP4 receptor antagonist for the control
  of pain and inflammation associated with osteoarthritis in dogs. Galliprant® has been granted
  marketing authorization by the European Commission on January 11, 2018 and Elanco launched the
  sales on April 2019.
  
  
  Supplementary Protection Certificate (SPC)
  In major countries around the world, a patent generally expires after 20 years following submission
  of the patent application. However, the patent exclusivity periods for pharmaceuticals may be
  extended for a maximum of five years in order to compensate for the time consuming and costly
  research and development. The SPC grant by France for Galliprant® represents a five-year
  extension of the therapy’s exclusive sales period.Germany granted SPC for Galliprant® on June 26, 2019, a veterinary drug product developed by
  Aratana Therapeutics Inc. (Aratana), and marketed by Aratana and Elanco Animal Health Inc.
  (Elanco). The SPC extends the period of exclusive sales rights for Galliprant® until February 28,
  2031. Additional SPCs for Galliprant® are currently under examination in several major EU
  countries. The grant in France marks the fifth approval in the EU, following grants received in Italy,
  Holland, Spain and Germany.
  
  
  Galliprant®
  Galliprant® (grapiprant tablets) is a prostaglandin E2 (PGE2) EP4 receptor antagonist for the control
  of pain and inflammation associated with osteoarthritis in dogs. Galliprant® has been granted
  marketing authorization by the European Commission on January 11, 2018 and Elanco launched the
  sales on April 2019.
  
  
  Supplementary Protection Certificate (SPC)
  In major countries around the world, a patent generally expires after 20 years following submission
  of the patent application. However, the patent exclusivity periods for pharmaceuticals may be
  extended for a maximum of five years in order to compensate for the time consuming and costly
  research and development. The SPC grant by France for Galliprant® represents a five-year
  extension of the therapy’s exclusive sales period.

• patent2019/07/10

  India Approves Crystal Forms Patent for AskAt’s EP4 antagonist (AAT-007)

  AskAt received issuance of a Patent Certificate on June 11, 2019 from the Indian Patent
  Office (IPO) in connection with the Application No. 9939/DELNP/2014, a crystal forms
  patent for the company’s EP4 antagonist (AAT-007)

• business2019/06/05

  EP4 Antagonist AAT-007 Clinical Study in Oncology Initiated in the People's Republic of China

  Ningbo NewBay Medical Technology Co., Ltd. (Headquarters in Ningbo, China, CEO: Zhenhai Shen; NewBay), announced that NewBay initiated a Phase I clinical study of the EP4 antagonist AAT-007 (generic name: grapiprant) in the People’s Republic of China (China) on June 4, 2019. NewBay is a subsidiary of Ningbo Tai Kang Medical Technology Co., Ltd. (Tai Kang) which licensed AT-007 from AskAt Inc. for cancer therapy in China.

• patent2019/06/03

  Galliprant® Granted Supplementary Protection Certificate (SPC) in Germany

  Germany granted SPC for Galliprant® on May 14, 2019, a veterinary drug product developed by Aratana Therapeutics Inc. (Aratana), and marketed by Aratana and Elanco Animal Health Inc. (Elanco). The SPC extends the period of exclusive sales rights for Galliprant® until March 1, 2031. Additional SPCs for Galliprant® are currently under examination in several major EU countries. The grant in Germany marks the fourth approval in the EU, following grants received in Italy, Holland, and Spain.

• business2019/05/07

  Elanco Announces Agreement to Acquire Aratana Therapeutics

  On April 26, 2019 (U.S. EST), Elanco Animal Health Inc. (U.S., Elanco) announced that it signed an agreement to acquire Aratana Therapeutics (U.S., Aratana) in a stock transaction valued at $245 million.

• patent2019/05/07

  Canada Approves Formulation Patent for AskAt’s COX-2 Inhibitor (AAT-076)

  AskAt received a Notice of Allowance on April 17, 2019 from the Canadian Intellectual Property Office (CIPO) in connection with Application No. 2,852,618, a formulation patent for the company’s COX-2 inhibitor (AAT-076).

• business2019/04/12

  Galliprant® was Launched in EU for Canine Osteoarthritis-associated Pain

  GALLIPRANT®, an EP4 receptor antagonist, is now available in the EU as a drug for the treatment of pain associated with osteoarthritis in dogs. GALLIPRANT® was developed by Aratana Therapeutics in EU and its marketing authorization was allowed in January 2018. Elanco sells GALLIPRANT® in EU countries. In the US, GALLIPRANT® is second in market share (approximately 15%) within the competitive NSAID market and dispensed by more clinics than any other oral NSAID.

• patent2019/04/03

  AskAt Granted Use Patent for EP4 Receptor Antagonists for the Treatment of NASH-Associated Liver Cancer by the Japan Patent Office

  AskAt received a Notice of Allowance dated March 26, 2019 from the Japan Patent Office in connection with the Application No. 2018-516877, a use patent for AskAt’s EP4 receptor antagonists for the treatment of NASH-Associated Liver Cancer.

• patent2019/03/13

  Galliprant® Granted Supplementary Protection Certificate (SPC) in Spain

  Spain granted an SPC for Galliprant® on March 6, 2019, a veterinary drug product developed by Aratana Therapeutics Inc. (Aratana), and marketed by Aratana and Elanco Animal Health Inc. (Elanco) in the United States. The SPC extends the period of exclusive sales rights for Galliprant® until March 1, 2031. Additional SPCs for Galliprant® are currently under examination in several major EU countries. The grant in Spain marks the third approval in the EU, following grants received in Italy and Holland in August 2018.

• patent2019/02/03

  AskAt Granted Use Patent for EP4 Receptor Antagonist for the Treatment of Cancer by the China National Intellectual Property Administration

  AskAt received a Notice of Allowance dated January 18, 2019 from the China National Intellectual Property Administration (CNIPA) in connection with Application No. 201510982848.3, a use patent for AskAt’s EP4 receptor antagonist for the treatment of cancer.